Press Release |

Response to FDA Concerns

Today, the FDA released a misinformed statement about the safety of mifepristone.

President & CEO of Physicians for Reproductive Health, Dr. Jamila Perritt, responds:

“As an abortion provider, I am disappointed by the FDA’s medically unfounded concern around the advanced prescription of mifepristone, one of the medications used in a medication abortion. Research shows that when patients have access to the information they need about mifepristone and the support that they want in their own communities, they are safely able to take the medication through the support of telehealth, in-person in a clinic, without any support from medical providers, or some combination of these options.

“Abortion in all of its forms, including medication abortion, is extremely safe. These unnecessary restrictions and groundless concerns regarding the use of mifepristone and access that is needed amidst the continued attacks on our communities creates greater barriers to care and harm for the communities we serve. The FDA should follow the science and the medical evidence which supports decreasing barriers to accessing medication abortion, not increasing them.”